David Sharon

David Sharon

Partner

Life Sciences and Tech Expertise

David has extensive experience working with biotech, pharmaceutical, software, cybersecurity, fintech, and autonomous trucking companies through all stages of their growth.
Capital Markets, Corporate, and Securities Expertise

David has represented clients in a broad range of corporate and securities matters including IPOs, deSPACs and other offerings, corporate governance, and other transactional matters. He has also worked on numerous transactions as underwriter counsel.

David Sharon is a partner in Wilson Sonsini Goodrich & Rosati’s New York office, where he focuses on corporate and securities work for both public and private companies across all stages of growth. David’s broad capital markets experience includes initial public, follow-on, and secondary equity offerings; investment grade, high-yield, and convertible debt offerings; and private investment in public equity (PIPE) transactions.

He also counsels publicly held companies on general corporate representation, SEC compliance, disclosure matters, exchange-listing standards, and complex securities law issues, and frequently represents investment banks in their underwriting transactions.

Prior to joining Wilson Sonsini, David practiced law at Fried, Frank, Harris, Shriver & Jacobson LLP in New York.

Experience

Prior to joining Wilson Sonsini, David practiced law at Fried, Frank, Harris, Shriver & Jacobson LLP in New York.

Education

J.D., Cornell Law School, 2013
M.B.A., S.C. Johnson Graduate School of Management, Cornell University, 2013
B.S., Cornell University, School of Industrial and Labor Relations, 2009

Admissions

State Bar of New York

Credentials

Education

J.D., Cornell Law School, 2013
M.B.A., S.C. Johnson Graduate School of Management, Cornell University, 2013
B.S., Cornell University, School of Industrial and Labor Relations, 2009

Admissions

State Bar of New York

Recent Insights

Client Highlights

On August 2, 2024, Aurora Innovation, Inc., a self-driving vehicle technology company, announced the closing of its underwritten upsized public offering for total gross proceeds of approximately $483 million, before deducting underwriting discounts and commissions and other offering expenses. In the public offering, Aurora sold 134,166,667 shares of its Class A common stock at $3.60 per share, which includes the full exercise by the underwriters of their option to purchase up to 17,500,000 additional shares.

Learn More

Client Highlights

Ascentage Pharma Group International (Ascentage Pharma) and Takeda Pharmaceuticals International AG (Takeda International) entered into an exclusive option agreement on June 14, 2024, where Takeda International is granted with an exclusive option to enter into an exclusive license agreement for HQP1351 (olverembatinib), a core drug candidate of Ascentage Pharma. In connection with such exclusive global arrangement, Ascentage Pharma and Takeda International also entered into a securities purchase agreement, pursuant to which Takeda International made a HK$585.77 million (US$75 million) equity investment in Ascentage Pharma to subscribe 24,307,322 shares of Ascentage Pharma at a purchase price of HK$24.09850 per share. The closing of such equity investment took place on June 20, 2024.

Learn More

View All

Recent Events

Affiliated Programs

Join us for Brex Founder & VC Happy Hour in NYC and connect with fellow professionals and be part of a thriving community in New York during #TechWeek.

Learn More

Affiliated Programs

Calling all founders, operators and investors - please join us to kick off NY Tech Week with cocktails and conversations, while DJ Twin-T spins our favorite vinyl tracks!

Learn More